Nucleolin-binding F3-peptide-targeted liposomes containing doxorubicin showed a significant in vitro intracellular delivery in both cancer (MDA-MB-435S) and endothelial cells (HMEC-1), relative to the non-targeted counterpart, and the ability to limit tumor invasion into adjacent healthy tissues in nucleolin-overexpressing MDA-MB-435S-derived mammary fat pad-implanted tumors [18]. The gene discussed is NUCLEOLIN; the disease is cancer.